Valbiotis【ALVAL】銘柄情報

Valbiotis SA (ALVAL) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

0.85

( -2.52% )

買値

0.826

売値

0.868

出来高

211,583

0.82 日の範囲 0.869

0.535 52 週間の範囲 1.27

時価総額

20.109M

前日終値

0.872

始値

0.868

時刻

1500

0.85

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

171,788 €

発行済株式数

23,657,340

配当利回り

PER

-1.82

1 株当たり利益 (EPS)

-0.47

歳入

905k

純利益

-9.42M

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It al... Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. Additionally, the company offers e-commerce delivery service in Belgium and Luxembourg. Valbiotis SA was incorporated in 2014 and is based in Périgny, France. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.valbiotis.com

本社

Périgny, France

設立

2026

Valbiotis SA is listed in the Healthcare sector of the ユーロネクスト with ticker ALVAL. The last closing price for Valbiotis was 0.87 €. Over the last year, Valbiotis shares have traded in a share price range of 0.535 € to 1.27 €.

Valbiotis currently has 23,657,340 shares in issue. The market capitalisation of Valbiotis is 20.11 € million. Valbiotis has a price to earnings ratio (PE ratio) of -1.82.

Valbiotis meldet durchschlagenden Erfolg der internationalen multizentrischen Phase-II/III-Studie REVERSE-IT zu TOTUM•63: nachgewiesene Wirksamkeit bei Hauptrisikofaktor für Typ-2-Diabetes

Die Studie erreichte ihr Ziel beim primären Endpunkt, der Senkung des Nüchternblutzuckers – Risikofaktor für Typ-2-Diabetes, bei einer...

Valbiotis annonce le large succès de l’étude clinique de Phase II/III internationale multicentrique REVERSE-IT sur TOTUM•63 : efficacité démontrée sur le principal facteur de risque du diabète de type 2

L’étude atteint son objectif sur le critère principal, la réduction de la glycémie à jeun, facteur de risque du diabète de type 2, à la dose...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.038	-4.27927927928	0.888	0.899	0.82	123116	0.86678836	DE
4	-0.228	-21.1502782931	1.078	1.25	0.82	179232	1.0170622	DE
12	-0.196	-18.7380497132	1.046	1.27	0.82	184217	1.05622835	DE
26	0.172	25.3687315634	0.678	1.27	0.653	256232	1.02365363	DE
52	-0.022	-2.52293577982	0.872	1.27	0.535	244510	0.91636705	DE
156	-3.23	-79.1666666667	4.08	7.5	0.535	126873	1.56827509	DE
260	-6.03	-87.6453488372	6.88	7.5	0.535	79017	1.80023157	DE